Tyvaso and Orenitram, leading to [ 11% ] total revenue growth over full year 2024 and surpassing $3 billion in total revenue ...

Methodology that is not complete, as well as discrepancies regarding the proposed mode of action of lipoxin A4, are significant weaknesses.

That should be the basic one-two strategy for any lawyer seeking to challenge agency actions involving supposed delegations ...

Relative to standard stats, advanced stats are considered more complex and esoteric. But in recent years, advanced stats have become a greater part of the mainstream conversation.